Molecular targeted therapy in multiple sclerosis: Bench to bedside and bedside to bench

cellular and molecular anesthesia: from bench to bedside

cellular and molecular anesthesia: from bench to bedside in the current practice of anesthesia, each day, anesthesiologists deal with a great work: they use the cellular mechanisms of drug molecules to induce their desired effects for induction and maintenance of anesthesia to achieve appropriate tolerance of surgery and its pain, modulation of stress response, sedation needed for performing a ...

From bench to bedside

Because the microcirculation has emerged as an important reanimation target, appropriate methods to monitor the microcirculatory function are crucial. Several teams have now succeeded in crossing this bridge from bench to bedside, but the choice of the tissues of interest remains a debate. The potential accessible vascular beds that doctors could use in reanimation strategies and the relationsh...

Bench to bedside review

From Bench to Bedside

Since the initial experiments nearly a decade ago, remarkable progress has been made in the field of vascular gene transfer, and trials with human subjects already are under way. The potential of vascular wall gene transfer as therapy for various vascular diseases is considerable.1,2 The purpose of this review is 2-fold: (1) to delineate the methods and principles underlying vascular gene trans...

Asthma: bench to bedside

P108 Table Variable Asthmatic (n = 34) Mean (95% CI) Inflammatory (n = 20) Mean (95% CI) Non-inflammatory (n = 18) Mean (95% CI) Overall ANOVA Age (years) 49.9 (43.6 to 56.1) 54.1 (45.9 to 62.2) 50.2 (45.7 to 54.6) 0.577 Duration rhinitis (years) 15.9 (11.5 to 20.4) 14.3 (6.3 to 22.3) 17.7 (10.3 to 25.0) 0.773 Exhaled NO (ppb)* 34.3 (25.9 to 45.3) 48.2 (36.0 to 64.5) 15.4 (11.1 to 21.3) ,0.005 ...